2024 Biopharma Recap
Staying ahead means knowing what to do next. Zymewire’s 2024 Biopharma Recap moves beyond traditional reporting to reveal the actionable signals hidden within the data.
Explore key trends in biopharma funding, trial activity, and emerging opportunities—alongside a snapshot of significant developments from early 2025. See what others miss, and position yourself proactively in a rapidly changing industry.
Download our Recap
Funding Review
Explore comprehensive breakdowns across North America, Europe, and APAC, highlighting key investment shifts year over year and quarter by quarter. With detailed analyses by company size, therapeutic area, and clinical development stage, quickly pinpoint where funding is flowing and identify your next strategic opportunity.
Upcoming Clinical Trials
Gain an exclusive, forward-looking view into upcoming clinical trial activity with Zymewire’s unique tracking of upcoming studies. Explore breakdowns by region, therapeutic area, and clinical trial phase to anticipate emerging opportunities. Leverage this early visibility and position your organization to capture outsourcing demand before the competition.
Study Initiations & Closeouts
Understanding study initiations and closeouts gives you an early edge. By spotting new trials as soon as they launch, you can monitor their progress closely, staying prepared to connect with sponsors when results emerge. Similarly, keeping track of completed studies, especially those with positive outcomes, offers valuable clues about where sponsors might head next.
2025 Snapshot
Recognizing that 2025 is already underway, we’ve included a snapshot of significant biopharma developments from the first quarter of the year. This section covers major mergers and acquisitions, notable funding rounds, and strategic partnerships, providing additional context to help you interpret 2024’s data.